acrivastine and Pruritus

The response to the histamine hydrochloride prick skin test was studied in 24 healthy volunteers who received, in random order and at least four days apart, acrivastine (8 mg), terfenadine (120 mg), and placebo. The tests were performed on either side of the back before and at the time of administration (single dose), then every 30 minutes for two hours, and every hour for the following four hours. Evaluation was based on the mean of two measurements of the surface area of the wheal-and-flare reaction accompanied by assessment of topical pruritus. The response to histamine was decreased markedly in the two active treatment groups. Although within one hour of injection, the activity of both antihistamines was consistently greater than that of placebo, the kinetics of action of the two products nevertheless differed; indeed acrivastine was active against flare and wheal earlier (within 30 minutes); terfenadine proved to be more active than acrivastine only on flare and only at the later times (four, five, and six hours). The safety study primarily demonstrated drowsiness in one-fourth of the patients receiving placebo and active treatment.

Topics: Drug Hypersensitivity; Histamine; Histamine H1 Antagonists; Humans; Pruritus; Skin; Skin Tests; Terfenadine; Triprolidine

Topics: Adolescent; Adult; Benzhydryl Compounds; Clinical Trials as Topic; Dermatitis, Atopic; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Pruritus; Pyridines; Random Allocation; Terfenadine; Triprolidine